Evidence map›Paper›PMID 25034590›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2014

[Treatment progress for EGFR wild-type advanced non-small cell lung cancer].

Feng Ma, Xiaoyu Shi, Wei Meng, Jing Zhang, Lixia Zhao, Xiaohua He, Junfeng Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feng MaDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Xiaoyu ShiDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Wei MengDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Jing ZhangDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Lixia ZhaoDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Xiaohua HeDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Junfeng ZhaoDepartment of Medical Oncology, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of death from cancer in the world. The treatment remains one of the most challenging tasks in the medical world. The discovery and development of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer (NSCLC). But the efficacy of EGFR-TKI in EGFR wild-type patients is limited, and the limited EGFR mutation incidence also prompts researchers to study what is the best treatment choice for patients with NSCLC who are negative for EGFR mutations. This review will discuss the research status in treatment choice for EGFR wild-type NSCLC.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungErbB ReceptorsHumansLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID25034590
PMCPMC6000467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.